8 Feb 2022 09:34
Sensyne Health plc
("Sensyne" or the "Company")
Update on General Meeting
Confirmed cases of COVID-19 mean that General Meeting will be held as a closed meeting
Oxford, U.K. 8 February 2022: Sensyne Health plc (LSE:SENS) today announces that due to a number of confirmed COVID-19 cases, the Company's General Meeting to be held at 2.00 p.m. on Friday, 11 February 2022 (the "General Meeting") will now be held as a closed meeting, with the minimum number of members legally required to be present to form a quorum in accordance with the Company's articles of association. Shareholders will not be permitted to attend in person and are therefore advised not to travel to the General Meeting. The Company is taking these precautionary measures to safeguard its shareholders', stakeholders' and employees' health and make the General Meeting as safe and efficient as possible.
Shareholders are encouraged to submit their votes by proxy in advance and to appoint the Chair of the meeting as their proxy (rather than their own choice of person), with voting instructions, to ensure their vote is counted. Completed forms of proxy must be returned so as to be received by the Company's Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA by no later than 2.00 p.m. on 9 February 2022, as set out in the Notice of General Meeting contained within the Circular sent to shareholders on 26 January 2022. The Circular is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Shareholders' attention is again drawn to the importance of voting at the General Meeting.
A video link for virtual attendance is being made available to provide shareholders with the opportunity to listen to the General Meeting and to have their questions answered. If you would like to join the video conference, please contact CSCSensynehealth@consilium-comms.com by close of business on Wednesday, 9 February 2022.
-ENDS-
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Contact details:
Sensyne Health |
| ||
Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
Dr Christopher Golden James Steel
|
| ||
Liberum (Joint Broker) | |||
Phil Walker William Hall | + 44 (0) 20 3100 2000 | ||
Consilium Strategic Communications | |||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
SternIR | |||
Julie Seidel Julie.seidel@sternir.com | +1 (212) 362 1200 | ||